The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Open accessAbstract
BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. METHODS: In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed progression-free survival. RESULTS: The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001). The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001). Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%). CONCLUSIONS: Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, NCT02151981 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Own result · 13 Not checked yet · 8 Own method · 3 Own interpretation · 1 Sources not found · 1 Check pending
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of investigator assessment, the median response duration was 9.7 months (95% CI, 8.3 to 11.6) in the osimertinib group and 4.1 months (95% CI, 3.0 to 5.6) in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).”
- Also stated in: § EFFICACY · plain
“The response rate was significantly better in the osimertinib group (71%; 95% CI, 65 to 76) than in the platinum–pemetrexed group (31%; 95% CI, 24 to 40) (odds ratio, 5.39; 95% CI, 3.47 to 8.48; P<0.001) (Table 2).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § EFFICACY · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvement in outcomes with osimertinib over platinum–pemetrexed in the tumor and plasma ctDNA T790M-positive subgroup was similar to that in the intention-to-treat population.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most commonly reported adverse events in the platinum–pemetrexed group were nausea (in 67 patients [49%]), decreased appetite (in 49 [36%]), constipation (in 47 [35%]), and anemia (in 41 [30%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 67- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%).”
- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
“Fewer patients reported adverse events of grade 3 or more in the osimertinib group than in the platinum–pemetrexed group (63 [23%] vs. 64 [47%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a mixed model for repeated-measures analysis, patient-reported outcomes were better in the osimertinib group than in the platinum–pemetrexed group across five prespecified symptoms during the overall period from randomization until 6 months (Table S4 in the Supplementary Appendix).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar finding was observed in the subgroup of patients with T790M-positive status on both tumor and plasma analyses (89 of 116 patients [77%] vs. 22 of 56 patients [39%]; odds ratio, 4.96; 95% CI, 2.49 to 10.15; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaincorrelationaln = 116 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Osimertinib was associated with a lower rate of adverse events leading to permanent discontinuation than was platinum–pemetrexed (in 19 patients [7%] and 14 patients [10%], respectively).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plaincorrelationaln = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival among patients with tumor and plasma T790M-positive status was 8.2 months in the osimertinib group versus 4.2 months in the platinum–pemetrexed group (hazard ratio, 0.42; 95% CI, 0.29 to 0.61) (Fig. 1C).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fatal adverse events were reported in 4 patients in the osimertinib group (respiratory failure in 2, pneumonitis in 1, and ischemic stroke in 1). One fatal adverse event of hypovolemic shock was reported in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 7
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A prolongation in the QT interval was recorded in 10 patients (4%) in the osimertinib group and 1 patient (1%) in the platinum–pemetrexed group, with all events of grade 1 or 2 in severity except for one grade 3 event in the osimertinib group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratio for progression-free survival favored osimertinib across all predefined subgroups that were analyzed (hazard ratio, <0.50 for each subgroup) (Fig. 2), including patients with CNS metastases (median duration of progression-free survival, 8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49) (Fig. 1B).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The duration of progression-free survival according to blinded independent central review was consistent with the investigator-assessed durations, with a median of 11.0 months versus 4.2 months (adjusted hazard ratio, 0.28; 95% CI, 0.20 to 0.38; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interstitial lung disease–like adverse events were reported in 10 patients (4%) in the osimertinib group (nine events of grade 1 or 2 in severity and one death) and in 1 patient (1%) in the platinum–pemetrexed group (one grade 3 event).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the patients who underwent randomization were included in the intention-to-treat population, which was used for all efficacy analyses.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, adverse events tended to be more severe in the platinum–pemetrexed group, despite the longer treatment duration with osimertinib.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety analysis included all the patients in the intention-to-treat population who had received at least one dose of a trial drug and for whom data were available after the administration of the drug.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The presence of the T790M variant reduces binding of first-generation or second-generation EGFR-TKIs to the ATP-binding pocket of EGFR, thereby reducing EGFR-TKI–mediated inhibition of downstream signaling and potentially leading to disease progression.17–19”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [17] Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070– 5. 18227510 PMC2538882 source
- Not checked yetcites [18] Sos ML, Rode HB, Heynck S, Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010; 70: 868– 74. 20103621 source
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These findings were confirmed in a pooled analysis of two subsequent phase 2 studies of osimertinib (at a dose of 80 mg once daily) in 411 patients with T790M-positive non–small-cell lung cancer, in which the response rate was 66% on blinded independent central review and the median duration of progression-free survival was 11.0 months.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
plainn = 411- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonisation), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We determined that 221 events of progression or death would provide a power of 80% to reject the null hypothesis of no significant difference in the duration of progression-free survival between the two treatment groups, assuming a treatment effect hazard ratio of 0.67 with a P value of 0.05 indicating two-sided statistical significance.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Osimertinib is an oral, irreversible EGFR-TKI that is selective for both EGFR and T790M resistance mutations with activity in the central nervous system (CNS).19–21”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
- Not checked yetcites [20] Ballard P, Yates JW, Yang Z, Pre-clinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22: 5130– 40. 27435396 source
- Not checked yetcites [21] Yang JC-H, Kim D-W, Kim S-W, Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 2016; 34: Suppl: 9002 abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Among patients with advanced non–small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy.1–4”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [1] Masters GA, Temin S, Azzoli CG, Systemic therapy for Stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015; 33: 3488– 515. 26324367 PMC5019421 source
- Not checked yetcites [2] Novello S, Barlesi F, Califano R, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: Suppl 5: v1– v27. 27664245 source
- Not checked yetcites [3] Tan DS, Yom SS, Tsao MS, The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016; 11: 946– 63. 27229180 source
- Not checked yetcites [4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC (version 3.2017). 2016 (http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). 28188192 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis of progression-free survival by blinded independent central review was conducted.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL END POINTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients were stratified according to Asian or non-Asian race and were randomly assigned in a 2:1 ratio to receive oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL DESIGN AND TREATMENT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In AURA3, the safety profile for osimertinib was consistent with that reported previously and differed from that in the platinum–pemetrexed group.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the phase 1 component of AURA, a phase 1/2 trial (ClinicalTrials.gov number, ), the objective response rate for osimertinib in patients with T790M-positive non–small-cell lung cancer was 61%; the median duration of progression-free survival was 9.6 months.22”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [22] Jänne PA, Yang JC-H, Kim D-W, AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med 2015; 372: 1689– 99. 25923549
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Platinum-pemetrexed was the standard of care for patients with T790M-positive advanced NSCLC after first-line EGFR-TKI at the time of trial initiation.
“Chemotherapy was the standard control at the time of trial initiation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In T790M-positive tumors, following progression after first- or second-generation EGFR TKIs, second-line osimertinib has demonstrated significant efficacy compared with chemotherapy (median PFS: 10.1 vs 4.4 months; HR, 0.30 (95% CI, 0.23‒0.40), P < 0.001).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [48]
Experimental — accuracy not yet measuredIn the citing paper
“In addition to being used alone, osimertinib is also being studied in combination with other targeted therapies for NSCLC, such as inhibitors of the Met, Bcl-2, and MAPK pathways.138–140”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [140]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“In a randomized phase III trial[3], osimertinib significantly improved both progression-free survival (PFS) and objective response rate (ORR) when compared to platinum-pemetrexed chemotherapy for T790M-positive non-small cell lung cancer (NSCLC) after progression on 1st or 2nd generation EGFR-TKIs.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [3]
In the citing paper
“In the AURA3 phase III trial, osimertinib demonstrated signi fi cantly higher ef fi cacy than platinum-based chemotherapy in patients with T790M-positive NSCLC. 14”
From Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) (2020) · cites this paper as [14]
In the citing paper
“Osimertinib was granted accelerated approval by the FDA in 2015 as a second-line treatment for NSCLC, and was approved as a first-line treatment for metastatic NSCLC in 2018 (ref.49).”
From Advances in covalent drug discovery (2022) · cites this paper as [49]
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Research works printed but not linked: 1
- Soria J, 2015, J Thorac Oncol, 10, S207
Cited by
Sorted by citations
Items 501–600 of 1,003
Yonesaka, K. (2021) · Cancers · doi:10.3390/cancers13051047 · Cited by 55
Liu, Y., Lai, M., Li, S., Wang, Y., Fěng, F., Zhang, T., Tong, L., Zhang, M., Chen, H., Chen, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.15229 · Cited by 56
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
Haratake, N., Ozawa, H., Morimoto, Y., Yamashita, N., Daimon, T., Bhattacharya, A., Wang, K., Nakashoji, A., Isozaki, H., Shimokawa, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.017 · Cited by 54
Leonetti, A., Verzè, M., Minari, R., Perrone, F., Gnetti, L., Bordi, P., Pluchino, M., Nizzoli, R., Azzoni, C., Bottarelli, L., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02475-9 · Cited by 54
Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
Lamb, Y. N., & Scott, L. J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0519-0 · Cited by 54
Hochmair, M. J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0566-1 · Cited by 55
Lee, C. K., Novello, S., Rydén, A., Mann, H., & Mok, T. S. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.2293 · Cited by 55
Self-citationComparison of Treatment Recommendations by Molecular Tumor Boards Worldwide
Rieke, D. T., Lamping, M., Schuh, M. R., Tourneau, C. L., Basté, N., Burkard, M. E., Metzeler, K. H., Leyvraz, S., & Keilholz, U. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00098 · Cited by 54
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid, S., Klingbiel, D., Aeppli, S., Britschgi, C., Gautschi, O. P., Pless, M., Rothschild, S. I., Wannesson, L., Janthur, W.-D., Förbs, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.020 · Cited by 54
Berghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 56
Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 56
Qin, Q., Li, X., Liang, X., Zeng, L., Wang, J., Sun, L., & Zhong, D. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13521 · Cited by 55
Jenkins, S., Chih-Hsin Yang, J., Jänne, P. A., Thress, K. S., Yu, K., Hodge, R., Weston, S., Dearden, S., Patel, S., Cantarini, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.002 · Cited by 53
Self-citationDetection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
Rossi, G., Jocollé, G., Conti, A., Tiseo, M., Marino, F. Z., Donati, G., Franco, R., Bono, F., Barbisan, F., & Facchinetti, F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s120172 · Cited by 54
Khattab, M. N. M., Mansour, H. M., Fawzy, H. M., & El-Khatib, A. S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332132 · Cited by 53
Attili, I., Corvaja, C., Spitaleri, G., Signore, E. D., Aliaga, P. T., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15205079 · Cited by 56
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
written on behalf of the AME Lung Cancer Collaborative Group, Jiang, T., Su, C., Ren, S., Cappuzzo, F., Rocco, G., Palmer, J. D., van Zandwijk, N., Blackhall, F. H., Le, X., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.61 · Cited by 53
He, Y., Zhang, X., Jia, K., Dziadziuszko, R., Zhao, S., Deng, J., Wang, H., Hirsch, F. R., & Zhou, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.15 · Cited by 54
Self-citationLi, Y.-L., Ding, K., Hu, X., Wu, L., Zhou, D., Rao, M., Lin, N., & Zhang, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14609 · Cited by 53
Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
Sayegh, N., Yirerong, J., Agarwal, N., Addison, D., Fradley, M. G., Cortes, J. E., Weintraub, N. L., Sayed, N., Raval, G. G., & Guha, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01845-2 · Cited by 52
Nakatani, K., Yamaoka, T., Ohba, M., Fujita, K., Arata, S., Kusumoto, S., Taki-Takemoto, I., Kamei, D., Iwai, S., Tsurutani, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0591 · Cited by 55
Bordi, P., Re, M. D., Minari, R., Rofi, E., Buti, S., Restante, G., Squadrilli, A., Crucitta, S., Casartelli, C., Gnetti, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.017 · Cited by 52
Hayakawa, D., Takahashi, F., Mitsuishi, Y., Tajima, K., Hidayat, M., Winardi, W., Ihara, H., Kanamori, K., Matsumoto, N., Asao, T., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13255 · Cited by 53
Zhao, P., Zhang, J., Wu, A., Zhang, M., Zhao, Y., Tang, Y., Wang, B., Chen, T., Li, F., Zhao, Q., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.052 · Cited by 52
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Li, X., Chen, C., Wang, Z., Liu, J., Sun, W., Shen, K., Lv, Y., Zhu, S., Zhan, P., Lv, T., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02075-8 · Cited by 52
Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
Ohtaki, Y., Shimizu, K., Suzuki, H. Y., Suzuki, K., Tsuboi, M., Mitsudomi, T., Takao, M., Murakawa, T., Ito, H., Yoshimura, K., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.037 · Cited by 54
Qin, Q., Li, X., Liang, X., Zeng, L., Wang, J., Sun, L., & Zhong, D. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13906 · Cited by 52
de Langen, A. J., Jebbink, M., Hashemi, S. M. S., Kuiper, J. L., de Bruin-Visser, J., Monkhorst, K., Thunnissen, E., & Smit, E. F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0194-7 · Cited by 51
Takahashi, A., Seike, M., Chiba, M., Takahashi, S., Nakamichi, S., Matsumoto, M., Takeuchi, S., Minegishi, Y., Noro, R., Kunugi, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33190-8 · Cited by 51
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
Li, B. T., Daly, B., Gospodarowicz, M. K., Bertagnolli, M. M., Brawley, O. W., Chabner, B. A., Fashoyin‐Aje, L. A., de Claro, R. A., Franklin, E. F., Mills, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01775-6 · Cited by 51
Self-citationHobor, S., Bakir, M. A., Hiley, C. T., Skrzypski, M. T., Frankell, A. M., Bakker, B., Watkins, T. B. K., Markovets, A. A., Dry, J. R., Brown, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47606-9 · Cited by 51
Mancini, M., Gal, H., Gaborit, N., Mazzeo, L., Romaniello, D., Salame, T. M., Lindzen, M., Mahlknecht, G., Enuka, Y., Burton, D. G. A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708076 · Cited by 52
Ariyasu, R., Nishikawa, S., Uchibori, K., Oh‐hara, T., Yoshizawa, T., Dotsu, Y., Koyama, J., Saiki, M., Sonoda, T., Kitazono, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.018 · Cited by 51
Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma
Maemura, K., Watanabe, K., Ando, T., Hiyama, N., Sakatani, T., Amano, Y., Kage, H., Nakajima, J., Yatomi, Y., Nagase, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13742 · Cited by 51
MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R
Zhang, Y., Huang, S., Guo, Y., & Li, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.059 · Cited by 51
Jiao, L., Xu, J., Sun, J., Chen, Z., Gong, Y., Bi, L., Lu, Y., Yao, J., Zhu, W., Hou, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00732 · Cited by 51
Yu, F., Ni, J., Zeng, W., Zhou, Y., Guo, T., Zeng, Y., Zhao, Y., Li, S., Li, Y., Yang, X., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.05.125 · Cited by 52
Yu, H. A., Paz-Ares, L. G., Yang, J. C., Lee, K. H., Garrido, P., Park, K., Kim, J.-H., Lee, K. H., Mao, H., Wijayawardana, S. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1690 · Cited by 50
Tanaka, K., Asahina, H., Kishimoto, J., Miyata, Y., Uchida, T., Watanabe, K., Hamai, K., Harada, T., Tsubata, Y., Sugawara, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.019 · Cited by 50
Koga, T., Suda, K., & Mitsudomi, T. (2022) · Cancer Science · doi:10.1111/cas.15263 · Cited by 50
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
Shields, M. D., Chen, K., Dutcher, G., Patel, I., & Pellini, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169006 · Cited by 51
Yang, S., Lin, C., Stehr, H., Long, S., Kong, C. S., Berry, G. J., Zehnder, J. L., & Kunder, C. A. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.10.007 · Cited by 50
Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
Carlisle, J. W., & Ramalingam, S. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0626 · Cited by 50
Self-citationTong, X., Tanino, R., Sun, R., Tsubata, Y., Okimoto, T., Takechi, M., & Isobe, T. (2019) · Respiratory Research · doi:10.1186/s12931-019-1244-2 · Cited by 50
Pharmacogenomics in the era of next generation sequencing – from byte to bedside
Russell, L. E., Zhou, Y., Almousa, A. A., Sodhi, J. K., Nwabufo, C. K., & Lauschke, V. M. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1909613 · Cited by 52
Hisakane, K., Seike, M., Sugano, T., Yoshikawa, A., Matsuda, K., Takano, N., Takahashi, S., Noro, R., & Gemma, A. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13943 · Cited by 50
Jain, A. S., Prasad, A., Pradeep, S., Dharmashekar, C., Achar, R. R., Silina, E. V., Stupin, V. A., Amachawadi, R. G. G., Prasad, S. K., Pruthvish, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741326 · Cited by 51
Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49
Lee, K.-K., Kim, Y., Jung, H. A., Lee, S., Ahn, J. S., Ahn, M., Park, K., Choi, Y., & Sun, J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.012 · Cited by 49
Self-citationMarin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 52
Horinouchi, H., Cho, B. C., Camidge, D. R., Goto, K., Tomasini, P., Li, Y., Vasilopoulos, A., Brunsdon, P., Hoffman, D., Shi, W., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.001 · Cited by 49
A scoping review of factors influencing the implementation of liquid biopsy for cancer care
Sheriff, S., Saba, M., Patel, R., Fisher, G., Schroeder, T., Arnolda, G., Luo, D., Warburton, L., Gray, E. S., Long, G. V., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03322-w · Cited by 49
Progress in the Management of Advanced Thoracic Malignancies in 2017
Ferrara, R., Mezquita, L., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.002 · Cited by 50
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0264 · Cited by 49
Miller, T. E., Yang, M., Bajor, D. J., Friedman, J. D., Chang, R. Y. C., Dowlati, A., Willis, J. E., & Sadri, N. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205396 · Cited by 50
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Castellanos-Rizaldos, E., Zhang, X., Tadigotla, V. R., Grimm, D. G., Karlovich, C., Raez, L. E., & Skog, J. (2019) · Oncotarget · doi:10.18632/oncotarget.26885 · Cited by 49
Kato, Y. X., Hosomi, Y., Watanabe, K., Yomota, M., Kawai, S., Okuma, Y., Kubota, K., Seike, M., Gemma, A., & Okamura, T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.03 · Cited by 49
Guo, T., Ni, J., Yang, X., Li, Y., Li, Y., Zou, L., Wang, S., Liu, Q., Chu, L., Chu, X., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.12.042 · Cited by 50
Ma, X., Bellomo, L. P., Magee, K., Bennette, C. S., Tymejczyk, O., Samant, M. K., Tucker, M., Nussbaum, N. C., Bowser, B. E., Kraut, J. S., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01659-0 · Cited by 49
Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 52
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48
Bertino, E. M., Gentzler, R. D., Clifford, S. E., Kolesar, J., Muzikansky, A., Haura, E. B., Piotrowska, Z., Camidge, D. R., Stinchcombe, T. E., Hann, C. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4084 · Cited by 48
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Bian, D., Sun, L., Hu, J., Duan, L., Xia, H., Zhu, X., Sun, F., Zhang, L., Yu, H., Xiong, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40349-z · Cited by 49
Huang, D., Deng, H., Zhou, J., Wang, G. A., Lei, Q., Guo, C., Peng, W., Liang, P., Shen, C., Ying, B., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05879 · Cited by 48
Regulatory role of CD39 and CD73 in tumor immunity
Kaplinsky, N., Williams, K., Watkins, D., Adams, M., Stanbery, L., & Nemunaitis, J. J. (2024) · Future Oncology · doi:10.2217/fon-2023-0871 · Cited by 48
Facchinetti, F., Loriot, Y., Brayé, F., Vasseur, D., Bahleda, R., Bigot, L., Barbé, R., Nobre, C., Combarel, D., Michiels, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1834 · Cited by 48
Tsakonas, G., Petris, L. D., & Ekman, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.004 · Cited by 48
Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.009 · Cited by 48
Sakuma, Y. (2017) · Pathology International · doi:10.1111/pin.12553 · Cited by 48
Kawamura, T., Kenmotsu, H., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Naito, T., Murakami, H., Omae, K., Mori, K. P., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.07.002 · Cited by 48
Xu, J., Wang, J., & Zhang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21164 · Cited by 52
Pasini, L., & Ulivi, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070998 · Cited by 48
Wan, Y., Yao, Z., Chen, W., & Li, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s230954 · Cited by 48
Floc’h, N., Lim, S., Bickerton, S., Ahmed, A., Orme, J. P., Urosevic, J., Martin, M. J., Cross, D. A. E., Cho, B. C., & Smith, P. D. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0103 · Cited by 48
Uchiyama, A. A. T., Silva, P. A. I. A., Lopes, M. S. M., Yen, C. T., Ricardo, E. D., Mutão, T. S., Pimenta, J. R., Machado, L. M., Shimba, D. S., & Peixoto, R. D. (2021) · Current Oncology · doi:10.3390/curroncol28010076 · Cited by 48
Hirsh, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017753338 · Cited by 47
Laurie, S. A., Banerji, S. O., Blais, N., Brule, S. Y., Cheema, P. K., Cheung, P., Daaboul, N., Hao, D., Hirsh, V., Juergens, R. A., et al. (2019) · Current Oncology · doi:10.3747/co.26.4116 · Cited by 48
Bertoli, E., Carlo, E. D., Conte, A. D., Stanzione, B., Revelant, A., Fassetta, K., Spina, M., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136936 · Cited by 48
Du, Z., Kan, H., Sun, J., Liu, Y., Gu, J., Akemujiang, S., Zou, Y., Jiang, L., Wang, Q., Li, C., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101266 · Cited by 47
EGFR T790M: revealing the secrets of a gatekeeper
Ko, B., Paucar, D., & Halmos, B. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s117944 · Cited by 47
Li, W., Qiu, T., Guo, L., Ling, Y., Gao, Y., Ying, J., & He, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.005 · Cited by 47
Wrona, A., Dziadziuszko, R., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.011 · Cited by 48
Protein-altering germline mutations implicate novel genes related to lung cancer development
Ji, X., Mukherjee, S., Landi, M. T., Bossé, Y., Joubert, P., Zhu, D. K., Gorlov, I. P., Xiao, X., Han, Y., Gorlova, O. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15905-6 · Cited by 47
Self-citationRoles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48
Jünger, S. T., Hoyer, U. C. I., Schaufler, D., Laukamp, K. R., Goertz, L., Thiele, F. O., Grunz, J., Schlamann, M., Perkuhn, M., Kabbasch, C., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27741 · Cited by 48
Page, R. D., Drusbosky, L. M., Dada, H. I., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.001 · Cited by 47
Self-citationPassiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
Pan, Q., Lu, Y., Li, X., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00792 · Cited by 48
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
Park, S. E., Noh, J. M., Kim, Y. J., Lee, H. S., Cho, J. H., Lim, S. W., Ahn, Y. C., Pyo, H., Choi, Y., Han, J., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.125 · Cited by 46
Self-citationErickson, A. W., Brastianos, P. K., & Das, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1617 · Cited by 46
Monica, S. L., Fumarola, C., Cretella, D., Bonelli, M. A., Minari, R., Cavazzoni, A., Digiacomo, G., Galetti, M., Volta, F., Mancini, M., et al. (2020) · Cancers · doi:10.3390/cancers13010006 · Cited by 46
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Sorolla, M. A., Sorolla, A., Parisi, E., Salud, A., & Porcel, J. M. (2021) · Cancers · doi:10.3390/cancers13112798 · Cited by 46
Ben-Aharon, O., Magnezi, R., Leshno, M., & Goldstein, D. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0175 · Cited by 47
Shan, Y., Ni, Q., Zhang, Q., Zhang, M., Wei, B., Cheng, L., Zhong, C., Wang, X., Wang, Q., Liu, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.014 · Cited by 45
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 47
Metadata
- Authors
- Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., Lee, C. K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., & Papadimitrakopoulou, V. A.
- Affiliations
- Army Medical University (CN)
- Emory University (US)
- Goethe University Frankfurt (DE)
- AstraZeneca (United Kingdom) (GB)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-02-16
- Volume
- 376
- Issue
- 7
- Pages
- 629-640
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6762027
- OpenAlex
- W2560717039
- Semantic Scholar
- bd8840946a65bec6d407a96092eda55497e49a58
- Cited by
- 3,379
- References
- 25
- Citations by year
- 2026: 198 · 2025: 280 · 2024: 301 · 2023: 318 · 2022: 410 · 2021: 438 · 2020: 404 · 2019: 365 · 2018: 389 · 2017: 268
- FWCI
- 305.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- Cancer Research UK (20465)
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, pemetrexed, carboplatin, cisplatin, second-line therapy, progression-free survival, central nervous system metastasis, brain metastases, objective response rate, adverse events
- MeSH terms
- Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Platinum, Pyrimidines, Disease-Free Survival, Young Adult, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
